BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
Reprints
Eli Lilly & Co. is slashing prices on its most-prescribed insulins and capping out-of-pocket costs for patients amid pressure from consumers and the Biden administration, Axios reports. The prices of Humalog, the company's top insulin product, and Humulin will fall 70% in the fourth quarter, according to the company. The price of generic insulin lispro, which is the same product as Humalog, will drop May 1 to $25 a vial, which Lilly says is less than Humalog cost in 1999. Lilly also said it would cap out-of-pocket costs for its insulin at $35 a month at some retail pharmacies.
1. TPA exec pleads guilty to embezzling client health care funds
2. Report warns of high costs if Medicare expanded to cover anti-obesity drugs
3. Top health insurance startups posted combined $2 billion in losses in 2022
5. Local governments opting out of Colorado paid leave program
6. Cerebral discloses sharing mental health patient info with social media giants